FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:120-121 July 8, 2004 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lipshultz, S. E. PubMed Citation

More than 70 percent of children who are treated for childhood cancer can be cured. For long-term survivors, possible late effects of treatment and their consequences for the quality of life are a major concern. Cardiotoxic effects of anthracyclines are among the most frequent and serious adverse effects of the treatment of childhood cancer. Anthracyclines such as daunorubicin, epirubicin, and doxorubicin have been used for more than 30 years, and nearly 60 percent of children with cancer are currently being treated with such agents.

The mechanisms behind cardiotoxic effects are not fully understood, but lipid peroxidation and the generation of . . . [Full Text of this Article]

Source Information

From the Department of Pediatric Oncology, Emma Children's Hospital and Academic Medical Center, University of Amsterdam, Amsterdam.

This article has been cited by other articles:

• Dickerman, J. D. (2007). The Late Effects of Childhood Cancer Therapy. Pediatrics 119: 554-568 [Abstract] [Full Text]  
• Boice, J. D. Jr (2007). An Affair of the Heart. JNCI J Natl Cancer Inst 99: 186-187 [Full Text]  
• (2004). Preventing Myocardial Injury in Doxorubicin-Treated Children. Journal Watch Cardiology 2004: 4-4 [Full Text]  
• Pui, C.-H., Schrappe, M., Ribeiro, R. C., Niemeyer, C. M. (2004). Childhood and Adolescent Lymphoid and Myeloid Leukemia. ASH Education Book 2004: 118-145 [Abstract] [Full Text]